Warfarin Pharmacogenetics A Rising Tide for Its Clinical Value

被引：53

作者：

Johnson, Julie A. ^{[1
,2
]}

机构：

[1] Univ Florida, Ctr Pharmacogen, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA

[2] Univ Florida, Ctr Pharmacogen, Dept Med, Gainesville, FL 32610 USA

来源：

CIRCULATION | 2012年 / 125卷 / 16期

关键词：

Editorials; pharmacogenetics; polymorphism genetics; warfarin; ATRIAL-FIBRILLATION; ANTICOAGULATION;

D O I：

10.1161/CIRCULATIONAHA.112.100628

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1964 / 1966

页数：3

共 10 条

[1] A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) [J].

Anderson, Jeffrey L. ;

Horne, Benjamin D. ;

Stevens, Scott M. ;

Woller, Scott C. ;

Samuelson, Kent M. ;

Mansfield, Justin W. ;

Robinson, Michelle ;

Barton, Stephanie ;

Brunisholz, Kim ;

Mower, Chrissa P. ;

Huntinghouse, John A. ;

Rollo, Jeffrey S. ;

Siler, Dustin ;

Bair, Tami L. ;

Knight, Stacey ;

Muhlestein, Joseph B. ;

Carlquist, John F. .

CIRCULATION, 2012, 125 (16) :1997-+

[2] Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) [J].

Ansell, Jack ;

Hollowell, Jennifer ;

Pengo, Vittorio ;

Martinez-Brotons, Fernando ;

Caro, Jaime ;

Drouet, Ludovic .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2007, 23 (02) :83-91

[3]

FDA Drug Safety Communication, 2011, SAF REV POSTM REP SE

[4] Genetic Warfarin Dosing Tables Versus Algorithms [J].

Finkelman, Brian S. ;

Gage, Brian F. ;

Johnson, Julie A. ;

Brensinger, Colleen M. ;

Kimmel, Stephen E. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (05) :612-618

[5] Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial [J].

French, Benjamin ;

Joo, Jungnam ;

Geller, Nancy L. ;

Kimmel, Stephen E. ;

Rosenberg, Yves ;

Anderson, Jeffrey L. ;

Gage, Brian F. ;

Johnson, Julie A. ;

Ellenberg, Jonas H. .

TRIALS, 2010, 11

[6] Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J].

Gage, B. F. ;

Eby, C. ;

Johnson, J. A. ;

Deych, E. ;

Rieder, M. J. ;

Ridker, P. M. ;

Milligan, P. E. ;

Grice, G. ;

Lenzini, P. ;

Rettie, A. E. ;

Aquilante, C. L. ;

Grosso, L. ;

Marsh, S. ;

Langaee, T. ;

Farnett, L. E. ;

Voora, D. ;

Veenstra, D. L. ;

Glynn, R. J. ;

Barrett, A. ;

McLeod, H. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :326-331

[7] New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs [J].

Garcia, David A. ;

Lopes, Renato D. ;

Hylek, Elaine M. .

THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1099-1105

[8] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing [J].

Johnson, J. A. ;

Gong, L. ;

Whirl-Carrillo, M. ;

Gage, B. F. ;

Scott, S. A. ;

Stein, C. M. ;

Anderson, J. L. ;

Kimmel, S. E. ;

Lee, M. T. M. ;

Pirmohamed, M. ;

Wadelius, M. ;

Klein, T. E. ;

Altman, R. B. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) :625-629

[9]

Klein TE, 2009, NEW ENGL J MED, V360, P753

[10] Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups [J].

Limdi, Nita A. ;

Wadelius, Mia ;

Cavallari, Larisa ;

Eriksson, Niclas ;

Crawford, Dana C. ;

Lee, Ming-Ta M. ;

Chen, Chien-Hsiun ;

Motsinger-Reif, Alison ;

Sagreiya, Hersh ;

Liu, Nianjun ;

Wu, Alan H. B. ;

Gage, Brian F. ;

Jorgensen, Andrea ;

Pirmohamed, Munir ;

Shin, Jae-Gook ;

Suarez-Kurtz, Guilherme ;

Kimmel, Stephen E. ;

Johnson, Julie A. ;

Klein, Teri E. ;

Wagner, Michael J. .

BLOOD, 2010, 115 (18) :3827-3834

← 1 →